LT2002035A - Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives - Google Patents
Mesoprogestins (progesterone receptor modulators) as a component of female contraceptivesInfo
- Publication number
- LT2002035A LT2002035A LT2002035A LT2002035A LT2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A
- Authority
- LT
- Lithuania
- Prior art keywords
- mesoprogestins
- female
- progesterone receptor
- component
- receptor modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the use of mesoprogestins for the production of a pharmaceutical for female contraception, to the pharmaceutical preparation for female contraception administering effective amounts of a mesoprogestin in a female desiring contraception. Optionally the mesoprogestin can be used in combination with an estrogen. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38613399A | 1999-08-31 | 1999-08-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
LT2002035A true LT2002035A (en) | 2002-10-25 |
LT5001B LT5001B (en) | 2003-03-25 |
Family
ID=23524305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LT2002035A LT5001B (en) | 1999-08-31 | 2002-03-26 | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1605949A2 (en) |
JP (1) | JP2003511399A (en) |
KR (1) | KR20020038745A (en) |
CN (1) | CN1384748A (en) |
AR (1) | AR025455A1 (en) |
AU (1) | AU781835B2 (en) |
BG (1) | BG106441A (en) |
BR (1) | BR0013711A (en) |
CA (1) | CA2383650A1 (en) |
CO (1) | CO5190694A1 (en) |
CZ (1) | CZ2002707A3 (en) |
EA (1) | EA006805B1 (en) |
EE (1) | EE200200103A (en) |
HR (1) | HRP20020265A2 (en) |
HU (1) | HUP0202515A3 (en) |
IL (1) | IL148415A0 (en) |
LT (1) | LT5001B (en) |
LV (1) | LV12940B (en) |
MX (1) | MXPA02002186A (en) |
NO (1) | NO20020998L (en) |
NZ (1) | NZ517470A (en) |
PE (1) | PE20010579A1 (en) |
PL (1) | PL353994A1 (en) |
SI (1) | SI20853A (en) |
SK (1) | SK2982002A3 (en) |
UA (1) | UA77150C2 (en) |
WO (1) | WO2001026603A2 (en) |
YU (1) | YU13902A (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10236405A1 (en) | 2002-08-02 | 2004-02-19 | Schering Ag | New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders |
DE50304970D1 (en) * | 2002-08-02 | 2006-10-19 | Schering Ag | PROGESTERONE RECEPTOR MODULATORS WITH INCREASED ANTIGONADOTROPIC ACTIVITY FOR THE FEMININE FERTILITY CONTROL AND HORMONE RESPONSE THERAPY |
EP1624848A4 (en) * | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | Methods of hormornal treatment utilizing extended cycle contraceptive regimens |
US20050215535A1 (en) * | 2004-03-24 | 2005-09-29 | Kristof Chwalisz | Sequential SPRM/progestin treatment |
TW200603813A (en) * | 2004-07-07 | 2006-02-01 | Wyeth Corp | Cyclic progestin regimens and kits |
DE102005050729A1 (en) * | 2005-10-19 | 2007-04-26 | Schering Ag | Method of preventive on-demand hormonal contraception |
BRPI1014035A2 (en) | 2009-04-14 | 2016-04-12 | Hra Pharma Lab | method for contraception. |
CN110548034A (en) * | 2019-07-12 | 2019-12-10 | 广州莎蔓生物科技有限公司 | Pregnancy-blocking medicine |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2054271A (en) | 1932-05-17 | 1936-09-15 | Schering Kahlbaum Ag | Production of crystallized hormone esters |
DE699310C (en) | 1936-11-20 | 1940-11-27 | Chemische Ind Ges | Process for the preparation of compounds of the estradiol type which are esterified in the 3-position |
US2225419A (en) | 1937-03-01 | 1940-12-17 | Schering Corp | Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols |
US2611773A (en) | 1951-08-21 | 1952-09-23 | Upjohn Co | Estradiol 17-cyclopenetanepropionate |
US2990414A (en) | 1957-03-26 | 1961-06-27 | Syntex Sa | 17-undecenoate of estradiol |
DE3337450A1 (en) | 1983-10-12 | 1985-04-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | PROSTAGLANDINE AND ANTIGESTAGE FOR PREGNANCY ABORT |
DK174071B1 (en) * | 1987-09-24 | 2002-05-21 | Jencap Res Ltd | Contraceptive preparation in the form of a package comprising unit doses |
US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
US5516769A (en) | 1993-02-19 | 1996-05-14 | The Medical College Of Hampton Roads | Method of inhibiting fertilization |
DE4332284C2 (en) * | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, process for their preparation and medicaments containing these compounds |
DE4332283A1 (en) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Novel 11-benzaldoximestradiene derivatives, processes for their preparation and medicaments containing these compounds |
DE4429398C2 (en) | 1994-08-09 | 1997-09-11 | Jenapharm Gmbh | Use of Estra-1,3,5 (10) -triene derivatives for hormonal contraception |
DE4429397C2 (en) | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds |
SK283662B6 (en) * | 1994-10-24 | 2003-11-04 | Schering Aktiengesellschaft | Competitive progesterone antagonists for regulating female fertility as required |
US6040340A (en) * | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
JP2000514785A (en) * | 1996-06-25 | 2000-11-07 | アクゾ・ノベル・エヌ・ベー | Progestogen-anti-progestogen prescription |
WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
DE19809845A1 (en) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituted 11beta-benzaldoxime-estra-4,9-diene-carbonic acid thiol esters, processes for their preparation and pharmaceutical preparations containing these compounds |
EP1175422A2 (en) * | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
-
2000
- 2000-08-31 HU HU0202515A patent/HUP0202515A3/en unknown
- 2000-08-31 UA UA2002032429A patent/UA77150C2/en unknown
- 2000-08-31 SI SI200020043A patent/SI20853A/en not_active IP Right Cessation
- 2000-08-31 WO PCT/IB2000/002053 patent/WO2001026603A2/en not_active Application Discontinuation
- 2000-08-31 EA EA200200284A patent/EA006805B1/en not_active IP Right Cessation
- 2000-08-31 CO CO00065517A patent/CO5190694A1/en not_active Application Discontinuation
- 2000-08-31 NZ NZ517470A patent/NZ517470A/en unknown
- 2000-08-31 AR ARP000104536A patent/AR025455A1/en unknown
- 2000-08-31 PL PL00353994A patent/PL353994A1/en not_active Application Discontinuation
- 2000-08-31 KR KR1020027002785A patent/KR20020038745A/en not_active Application Discontinuation
- 2000-08-31 EE EEP200200103A patent/EE200200103A/en unknown
- 2000-08-31 YU YU13902A patent/YU13902A/en unknown
- 2000-08-31 CZ CZ2002707A patent/CZ2002707A3/en unknown
- 2000-08-31 EP EP00991299A patent/EP1605949A2/en not_active Withdrawn
- 2000-08-31 IL IL14841500A patent/IL148415A0/en unknown
- 2000-08-31 MX MXPA02002186A patent/MXPA02002186A/en not_active Application Discontinuation
- 2000-08-31 BR BR0013711-1A patent/BR0013711A/en not_active IP Right Cessation
- 2000-08-31 CN CN00812308A patent/CN1384748A/en active Pending
- 2000-08-31 CA CA002383650A patent/CA2383650A1/en not_active Abandoned
- 2000-08-31 AU AU32150/01A patent/AU781835B2/en not_active Ceased
- 2000-08-31 PE PE2000000894A patent/PE20010579A1/en not_active Application Discontinuation
- 2000-08-31 SK SK298-2002A patent/SK2982002A3/en unknown
- 2000-08-31 JP JP2001529395A patent/JP2003511399A/en active Pending
-
2002
- 2002-02-26 BG BG06441A patent/BG106441A/en unknown
- 2002-02-28 NO NO20020998A patent/NO20020998L/en not_active Application Discontinuation
- 2002-03-26 LT LT2002035A patent/LT5001B/en not_active IP Right Cessation
- 2002-03-28 LV LVP-02-52A patent/LV12940B/en unknown
- 2002-03-28 HR HR20020265A patent/HRP20020265A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20020998D0 (en) | 2002-02-28 |
CO5190694A1 (en) | 2002-08-29 |
EA006805B1 (en) | 2006-04-28 |
IL148415A0 (en) | 2002-09-12 |
HUP0202515A2 (en) | 2002-12-28 |
HRP20020265A2 (en) | 2004-02-29 |
YU13902A (en) | 2006-01-16 |
AR025455A1 (en) | 2002-11-27 |
SK2982002A3 (en) | 2002-07-02 |
NO20020998L (en) | 2002-03-14 |
JP2003511399A (en) | 2003-03-25 |
BG106441A (en) | 2002-09-30 |
EP1605949A2 (en) | 2005-12-21 |
CA2383650A1 (en) | 2001-04-19 |
BR0013711A (en) | 2002-05-07 |
AU3215001A (en) | 2001-04-23 |
KR20020038745A (en) | 2002-05-23 |
PE20010579A1 (en) | 2001-06-04 |
EE200200103A (en) | 2003-04-15 |
MXPA02002186A (en) | 2002-09-02 |
SI20853A (en) | 2002-10-31 |
AU781835B2 (en) | 2005-06-16 |
LT5001B (en) | 2003-03-25 |
WO2001026603A3 (en) | 2002-01-17 |
WO2001026603A2 (en) | 2001-04-19 |
HUP0202515A3 (en) | 2004-06-28 |
NZ517470A (en) | 2004-03-26 |
CZ2002707A3 (en) | 2002-11-13 |
UA77150C2 (en) | 2006-11-15 |
PL353994A1 (en) | 2003-12-15 |
CN1384748A (en) | 2002-12-11 |
EA200200284A1 (en) | 2002-10-31 |
LV12940B (en) | 2003-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200605882A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
BG101553A (en) | Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives | |
TW200607798A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
HUP0103345A3 (en) | Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions | |
ATE307591T1 (en) | PREPARATIONS CONTAINING A STEROID HORMONE AND A STABILIZING AGENT IN NON-CRYSTALLINE FORM | |
WO2004110408A3 (en) | Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol | |
WO2000012623A3 (en) | Use of 5-th receptor antagonists for the treatment of parkinson's disease | |
LT2002035A (en) | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives | |
EP1090639A3 (en) | Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator | |
WO2000074649A3 (en) | Ophthalmic histamine compositions and uses thereof | |
YU14002A (en) | Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders | |
EA200601089A1 (en) | TRANSDERMAL DELIVERY OF HORMONES WITHOUT THE NEED TO USE AGENTS, STRENGTHENING PENETRATION | |
WO2001034126A3 (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
MXPA01011296A (en) | Contraceptive compositions containing indoline derivatives and progestational agents. | |
TW200640468A (en) | Pharmaceutical product for oral contraception | |
Prema | Haemoglobin levels in contraceptive users | |
WO1996028154A3 (en) | Use of anti-oestrogens as male contraceptives | |
Robb-Nicholson | By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer? | |
IL125983A0 (en) | Pharmaceutical composition comprising factor xiiia | |
JP2003502270A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC9A | Transfer of patents |
Owner name: SCHERING AKTIENGESELLSCHAFT, DE Effective date: 20030513 |
|
MM9A | Lapsed patents |
Effective date: 20080831 |